Clinical Professor of Medicine, UCLA-David Geffen School of Medicine
Cardiology
Dr. Norman E. Lepor, MD
|
|
Give Review
Dr. Norman E. Lepor works in the field of Cardiology. She attended Johns Hopkins University School of Medicine. Johns Hopkins University School of Medicine is a top medical university. Johns Hopkins University School of Medicine has a rank of 3 in research and a 29 in primary care She received 6 awards: "Top Doctors:LA Area", "CMS Meaningful Use Stage 1 Certification", "Top Doctors:Southern California", "Fellow (FACC)", "Super Doctor" and "Most Compassionate Doctor". Norman E. Lepor is also published. She has 88 publications published. The lastest publication: "The evolving utility of intracoronary ultrasound.' She accepts Medicare.
Publications
- The PCSK9 Inhibitors: A Novel Therapeutic Target Enters Clinical Practice.
- New vistas for the treatment of obesity: turning the tide against the leading cause of morbidity and cardiovascular mortality in the developed world.
- Hypertension. Left ventricular hypertrophy and cardiac function in patients with resistant hypertension.
- Venous disease: the missing link in cardiovascular medicine.
- The evolving utility of intracoronary ultrasound.
- Contrasts between intrathoracic pressures during external chest compression and cardiac massage.
- Stimulation of the efflux of L-glutamate from renal brush-border membrane vesicles by extravesicular potassium.
- Does nitroglycerin induce heparin resistance?
- Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart disease.
- Intravascular ultrasound imaging of ruptured atherosclerotic plaques in coronary arteries.
- Summary of the third report of the National Cholesterol Education Program Adult Treatment Panel III.
- Design and rationale of CONTRAST--a prospective, randomized, placebo-controlled trial of fenoldopam mesylate for the prevention of radiocontrast nephropathy.
- Radiocontrast nephropathy: the dye is not cast.
- Anorexigen-related cardiopulmonary toxicity.
- Radiocontrast nephropathy: managing the high-risk patient. Introduction.
- Effective and efficient strategies for coronary revascularization in the drug-eluting stent era.
- Antioxidants as adjuvant therapy for cardiovascular disease.
- Risk associated with "normal" blood pressure.
- Unusual presentation of an acute inferior myocardial infarction.
- Use of glycoprotein IIb/IIIa receptor inhibitors in acute coronary syndromes.
- Triglycerides and coronary atherosclerosis: implications for treatment of mixed dyslipidemias.
- Using of MRI in carotid artery plaque detection.
- Evaluation of second-generation drug-eluting stents.
- Computed tomography screening for coronary artery calcium in asymptomatic individuals.
- Assessing appropriateness of coronary intervention.
- Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention.
- The electrophysiological properties of ranolazine: a metabolic anti-ischemic drug or an energy-efficient antiarrhythmic agent?
- Combination ranolazine and dronedarone to suppress atrial fibrillation.
- Consequences of changes in medicine.
- Cardiac magnetic resonance imaging. Prognostic value of high-dose dobutamine stress MRI.
- Future of medicine in the United States is uncertain.
- An evidence-based algorithm for the use of B-type natriuretic testing in acute coronary syndromes.
- Differential diagnosis and overlap of acute chest discomfort and dyspnea in the emergency department.
- High prevalence of ultrasound detected carotid atherosclerosis in subjects with low Framingham risk score: potential implications for screening for subclinical atheros...
- Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women.
- Antiseptic skin agents for percutaneous procedures.
- Dyslipidemia. Treatment in patients with chronic kidney disease.
- Diabetes mellitus. Detection of ischemia.
- Statin therapy. Avoiding statin-related muscle side effects.
- Acute coronary syndromes. The interaction of proton pump inhibitors and clopidogrel.
- Percutaneous coronary intervention. Significance of troponin bump in PCI and safety of warfarin with dual antiplatelet therapy.
- Hypertension. A new risk score.
- Cardiovascular imaging to risk-stratify in chronic angina.
- Cardiac imaging. Multislice coronary computed tomography and magnetic resonance imaging in the cardiology practice.
- The QT Interval and Selection of Alpha-Blockers for Benign Prostatic Hyperplasia.
- Lipids, biomarkers, and noninvasive imaging of atherosclerotic disease activity in clinical trials.
- Chemotherapy and cardiotoxicity.
- Priceless clinical pearls in the performance of cardiac CT.
- Optimizing outcomes in CT imaging.
- Anticoagulation for acute coronary syndromes: from heparin to direct thrombin inhibitors.
- The rosiglitazone meta-analysis.
- Presence and severity of noncalcified coronary plaque on 64-slice computed tomographic coronary angiography in patients with zero and low coronary artery calcium.
- Primary prevention, treatment, and secondary prevention of late and very late stent thrombosis.
- Nesiritide for acute decompensated heart failure.
- Impact of chronic kidney disease and diabetes on percutaneous coronary intervention outcomes.
- Contemporary issues in the cath lab. Introduction.
- Practical guidelines for the use of anticoagulants in the catheterization laboratory.
- Therapeutic goals for effective platelet inhibition: a consensus document.
- Screening CT-coronary angiography: ready for prime time?
- Diabetes. Insulin glargine or rosiglitazone as add-on therapies.
- Obesity. Rimonabant trials confirm benefit.
- Microvolt T-wave alternans testing to target patients for ICD implantation and prevent sudden cardiac death.
- Myocardial infarction. Initial results from the EPHESUS trial.
- Piecing together the evidence on anemia: the link between chronic kidney disease and cardiovascular disease.
- Anemia: a modifiable risk factor for heart disease. Introduction.
- Diuretic therapy, natriuretic peptides, and heart failure.
- Meta-analysis of abciximab trials confirms benefit.
- Vascular disease and erectile dysfunction.
- Patients at risk. Tricuspid regurgitation and survival.
- Opportunities to improve outcomes in the heart failure patient: alleviating symptoms and prolonging life. Introduction.
- The emerging use of 16- and 64-slice computed tomography coronary angiography in clinical cardiovascular practice.
- The deadly triangle of anemia, renal insufficiency, and cardiovascular disease: implications for prognosis and treatment.
- Changing the guard in long-term anticoagulation: clinical and economic implications.
- An update on diagnostic criteria for diabetes and the metabolic syndrome.
- Diabetes mellitus. The sulfonylurea controversy: friend or foe?
- A review of pharmacologic interventions to prevent contrast-induced nephropathy.
- Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial.
- A prospective, nonrandomized, open-labeled pilot study investigating the use of magnesium in patients undergoing nonacute percutaneous coronary intervention with stent...
- Renal insufficiency. The prognostic value of renal function in patients with congestive heart failure and acute myocardial infarction.
- Patients at risk. Recent study findings on predicting and improving outcomes.
- Clinical impact of stent design.
- Diagnosis of coronary pseudoaneurysm by Optison.
- Congestive heart failure. Doppler imaging to predict beta-blocker performance.
- Coronary artery disease. Prevention with statin and niacin.
- Choice for stroke prevention.
- A review of contemporary prevention strategies for radiocontrast nephropathy: a focus on fenoldopam and N-acetylcysteine.
- Coronary artery disease treatment in the catheterization laboratory: the promise of an evolving new pharmaco-mechanical approach. Introduction.
Doctors Specialties
- Cardiology
Accepted Insurances
Awards
- Top Doctors:LA Area
- CMS Meaningful Use Stage 1 Certification
- Top Doctors:Southern California
- Fellow (FACC)
- Super Doctor
- Most Compassionate Doctor
Education
-
Cedars-Sinai Medical Center -
Johns Hopkins University School of Medicine
Hospital
-
Cedars-Sinai Medical Center
Drug Facts
| NPI NUMBER | 1013979673 | |
| NPPES Provider LastName | LEPOR | |
| NPPES Provider FirstName | NORMAN | |
| NPPES Provider ZIPCode | 902112222 | |
| NPPES Provider State | CA | |
| Specialty Description | Cardiology | |
| Total Claim Count | 4102.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1013979673 |
| Last Name Of The Provider | LEPOR |
| First Name Of The Provider | NORMAN |
| View All |
Similar Doctors
|
Dr. Amita R. Dharawat, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul J. Grodan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles F. Kivowitz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jon A. Kobashigawa, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Antoine Alhajje, MD |
|
|
Dr. Joshua Penn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen H. Lebowitz, MD
This Doctor is OpenDoctor Recommended.
|